|Bid||246.00 x 3000|
|Ask||247.60 x 800|
|Day's Range||244.62 - 245.82|
|52 Week Range||215.90 - 277.29|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||46.72|
|Forward Dividend & Yield||3.48 (1.51%)|
|Ex-Dividend Date||Sept 08, 2022|
|1y Target Est||N/A|
FRANKLIN LAKES, N.J., October 18, 2022--Regulatory News: BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biocorp (Paris:ALCOR), a medical device and delivery systems manufacturer based in France, today announced that they have signed an agreement with the aim of using connected technology to track adherence for self-administered drug therapies, like biologics.
NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that it has appointed Dr. Ellen Strahlman and Dr. Ram Palanki as new and independent members of its Board of Directors. With these appointments, the Eyenovia Board will expand to eight seats, from six currently. “I could not be more pleased to welcome Drs. Strahlman and Palanki to
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, is pleased to announce the integration of the BD HealthSight™ Analytics Solutions in Eastern Health facilities. Eastern Health will become the first healthcare authority in Canada to integrate BD HealthSight™, which aims to reduce the use of antibiotics and other medications in addition to helping healthcare providers identify emerging infections among patients.